Reduced Heart Rate Variability and New-Onset Hypertension

Insights Into Pathogenesis of Hypertension: The Framingham Heart Study

Jagmeet P. Singh, Martin G. Larson, Hisako Tsuji, Jane C. Evans, Christopher J. O’Donnell, Daniel Levy

Abstract—Heart rate variability (HRV) is a useful noninvasive tool to assess cardiac autonomic function. The purpose of this study was to (1) compare measures of HRV between hypertensive and normotensive subjects and (2) examine the role of HRV as a predictor of new-onset hypertension. The first 2 hours of ambulatory ECG recordings obtained from 931 men and 1111 women attending a routine examination at the Framingham Heart Study were processed for HRV. Three time-domain and 5 frequency-domain variables were studied: standard deviation of normal RR intervals (SDNN), percentage of differences between adjacent normal RR intervals exceeding 50 milliseconds, square root of the mean of squared differences between adjacent normal RR intervals, total power (0.01 to 0.40 Hz), high frequency power (HF, 0.15 to 0.40 Hz), low frequency power (LF, 0.04 to 0.15 Hz), very low frequency power (0.01 to 0.04 Hz), and LF/HF ratio. On cross-sectional analysis, HRV was significantly lower in hypertensive men and women. Among 633 men and 801 women who were normotensive at baseline (systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg and not receiving antihypertensive treatment), 119 men and 125 women were newly hypertensive at follow-up 4 years later. After adjustment for factors associated with hypertension, multiple logistic regression analysis revealed that LF was associated with incident hypertension in men (odds ratio per SD decrement [OR], 1.38; 95% confidence interval [CI], 1.04 to 1.83) but not in women (OR, 1.12; 95% CI, 0.86 to 1.46). SDNN, HF, and LF/HF were not associated with hypertension in either sex. HRV is reduced in men and women with systemic hypertension. Among normotensive men, lower HRV was associated with greater risk for developing hypertension. These findings are consistent with the hypothesis that autonomic dysregulation is present in the early stage of hypertension. (Hypertension. 1998;32:293-297.)

Key Words: heart rate ■ hypertension, essential ■ Framingham Heart Study ■ autonomic nervous system ■ pathogenesis

There is considerable evidence to suggest that the autonomic nervous system plays an important role in blood pressure regulation and in the development of hypertension. Spectral analysis of HRV can partially distinguish parasympathetic from sympathetic influences on the heart and may provide important insights into the role of the autonomic nervous system in the pathogenesis of essential hypertension.

Although previous studies from Framingham and elsewhere have identified abnormal HRV in systemic hypertension, there is a paucity of data examining the association between HRV and blood pressure. Also, even though sympathetic nervous system overactivity has been demonstrated in early hypertension, little is known about the impact of altered HRV on the development of new-onset hypertension. The purpose of this study was to (1) compare the measures of HRV in Framingham Heart Study subjects with and those without hypertension and (2) assess the role of HRV as a predictor of new-onset hypertension during 4 years of follow-up.

Methods

Subjects

The Framingham Heart Study is a prospective epidemiological study established in 1948 to evaluate potential risk factors for coronary heart disease. The original cohort included 5209 men and women aged 28 to 62 years. In 1971, 5124 additional subjects were entered into the Framingham Offspring Study. Study design and selection criteria have been published.

Subjects for the present study were original Framingham Heart Study participants and Offspring Study subjects who underwent ambulatory ECG recordings between 1983 and 1987 during a routine scheduled examination at the Framingham Heart Study clinic. Subjects were excluded if they met any of the following criteria: (1)
Selected Abbreviations and Acronyms

- HF = high frequency power
- HRV = heart rate variability
- LF = low frequency power
- LF/HF = ratio of low frequency to high frequency power
- OR = odds ratio
- pNN50 = percentage of differences between normal RR intervals >50 ms based on 2-hour recordings
- r-MSSD = root-mean-square of successive differences
- SDNN = standard deviation of normal RR intervals
- TP = total power

Heart Rate Variability and Hypertension

history or clinical evidence of myocardial infarction or congestive heart failure, (2) atrial fibrillation, (3) diabetes mellitus, (4) use of antihypertensive or cardioactive medication at the index examination, and (5) technically inadequate ambulatory ECG recordings. The diagnoses of myocardial infarction and congestive heart failure were established by a committee of 3 physicians who evaluated records from the Framingham Heart Study clinic examinations, interim hospitalizations, and visits to personal physicians in accordance with published criteria. At the index examination, body height and weight measurements, medical history, physical examination, and 12-lead resting and ambulatory ECG results were routinely obtained.

Blood Pressure Measurements

At each routine examination, blood pressure was measured in the left arm twice, with the subject in the seated position, by the examining physician using a mercury column sphygmomanometer. The averaged values were then used to derive the respective examination systolic and diastolic blood pressures. The index examination was the one performed at the time of the ambulatory ECG recording.

HRV Assessment

The first 2 hours of ambulatory ECG recordings were processed for HRV. All ambulatory recordings included 2 channels of ECG information and were obtained on standard 4-track cassette tapes with the use of either a Cardiodata PR2 or PR3 pace recorder (Cardiodata Corp). The tape speed was 1 mm/s, and 1 channel was used to record a 32-Hz crystal-controlled timing track. For analysis, the tapes were played back at 120 times real time on the Cardiodata/Mortara Mk5 Holter analysis system (Mortara Instrument Co), sampling each ECG channel at 180 samples per second. Beat-to-beat RR interval data were obtained from the “beat stream file.” A linearly interpolated beat was substituted for intervals of ectopic beats or artifact ≤2 RR intervals. The fast Fourier transform was calculated on 100-second blocks of RR interval data. A continuous curve was formed by linear interpolation between RR intervals; this was subjected to a Hamming window and resampled at 1.28 times per second. If there was a run of arrhythmia or artifact >1 beat long, the 100-second block was terminated, the partial block was discarded, and a new block was started at the end of the usable period. Power density spectrum was estimated by taking the sum of the power density spectra for age, body mass index, cigarette smoking, and alcohol consumption, as well as baseline systolic and diastolic blood pressures. Heart rate did not enter the model. Results are summarized by OR and 95% confidence interval, with the OR expressed for a 1-SD decrement in the log-transformed HRV variable. In addition, HRV measures were compared between subjects who developed hypertension and those who remained normotensive at the 4-year follow-up examination. An association was considered statistically significant at a value of $P < 0.05$. All analyses were done on a Sparcstation 2 (SUN Microsystems) using the Statistical Analysis System (SAS).

Results

Subjects Selected

HRV data were available for 2722 subjects; 567 subjects using antihypertensive medication and 113 with a history of myocardial infarction or congestive heart failure were excluded from analysis: therefore, 931 men and 1111 women were eligible for the study. For the analyses of incident hypertension, 472 subjects (245 men and 227 women) were excluded because of presence of hypertension at the index examination, and 136 subjects did not attend the examination 4 years later. Of the subjects eligible (633 men and 801 women) for the incidence study, 119 men and 125 women developed hypertension at the follow-up examination 4 years later.

Clinical and HRV Characteristics

At the index examination, subjects with hypertension were older than those with normal blood pressure (Table 1). After age adjustment, body mass index, baseline systolic and diastolic blood pressures, and mean heart rate were higher in hypertensive men and women compared with the normotensives. Alcohol consumption was higher in hypertensive men, whereas no significant difference was observed for smoking.
TABLE 1. Mean Age and Age-Adjusted Clinical Characteristics of Hypertensive and Normotensive Subjects at Index Examination

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>NT (n=886)</th>
<th>HTN (n=245)</th>
<th>NT (n=884)</th>
<th>HTN (n=227)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>48.4±0.5</td>
<td>56.7±0.6*</td>
<td>49.3±0.4</td>
<td>61.6±0.8*</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.4±0.2</td>
<td>27.7±0.3</td>
<td>24.5±0.2</td>
<td>26.0±0.3</td>
</tr>
<tr>
<td>Cigarettes/d</td>
<td>6.5±0.5</td>
<td>7.9±0.8</td>
<td>5.7±0.5</td>
<td>5.3±0.9</td>
</tr>
<tr>
<td>Alcohol, oz/wk</td>
<td>3.9±0.2</td>
<td>5.1±0.3†</td>
<td>2.0±0.2</td>
<td>2.1±0.3</td>
</tr>
<tr>
<td>Coffee, cups/d</td>
<td>2.7±0.1</td>
<td>2.5±0.2</td>
<td>2.0±0.8</td>
<td>1.8±0.2</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>120.5±0.5</td>
<td>143±0.7*</td>
<td>117±0.4</td>
<td>145±0.8*</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>77±0.3</td>
<td>89±0.5*</td>
<td>73±0.3</td>
<td>86±0.5*</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>71.0±0.4</td>
<td>74±0.6*</td>
<td>75.1±0.3</td>
<td>77.5±0.7*</td>
</tr>
</tbody>
</table>

NT indicates normotensive; HTN, hypertensive; BMI, body mass index; SBP, systolic blood pressure; and DBP, diastolic blood pressure. Results are expressed as mean±SEM.

TABLE 2. Comparison of Adjusted Measures of Heart Rate Variability Between Hypertensive and Normotensive Subjects at Index Examination

<table>
<thead>
<tr>
<th>Variable</th>
<th>NT (n=686)</th>
<th>HTN (n=245)</th>
<th>NT (n=884)</th>
<th>HTN (n=227)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ln SDNN</td>
<td>4.52±0.01</td>
<td>4.42±0.02*</td>
<td>4.46±0.01</td>
<td>4.36±0.02*</td>
</tr>
<tr>
<td>ln LF</td>
<td>6.82±0.02</td>
<td>6.62±0.04*</td>
<td>6.56±0.02</td>
<td>6.37±0.05†</td>
</tr>
<tr>
<td>ln HF</td>
<td>5.46±0.03</td>
<td>5.31±0.05§</td>
<td>5.48±0.03</td>
<td>5.31±0.05§</td>
</tr>
<tr>
<td>ln LF/HF</td>
<td>1.36±0.02</td>
<td>1.31±0.03</td>
<td>1.08±0.01</td>
<td>1.06±0.03</td>
</tr>
<tr>
<td>ln Very LF</td>
<td>7.63±0.02</td>
<td>7.47±0.02†</td>
<td>7.46±0.02</td>
<td>7.30±0.04‡</td>
</tr>
<tr>
<td>ln TP</td>
<td>8.10±0.02</td>
<td>7.93±0.04*</td>
<td>7.92±0.02</td>
<td>7.75±0.04‡</td>
</tr>
<tr>
<td>ln r-MSSD</td>
<td>3.43±0.02</td>
<td>3.34±0.03§</td>
<td>3.41±0.01</td>
<td>3.31±0.03§</td>
</tr>
<tr>
<td>ln pNN50</td>
<td>1.72±0.04</td>
<td>1.42±0.08‡</td>
<td>1.64±0.04</td>
<td>1.35±0.06§</td>
</tr>
</tbody>
</table>

NT indicates normotensive; HTN, hypertensive. All HRV measures are natural log (ln) transformed values, expressed as mean±SEM. All measures are adjusted for age, body mass index, smoking, and alcohol consumption.

*p<0.0001, †p<0.0005, §p<0.001, ‡p<0.01.

and coffee consumption (Table 1). After adjustment for the clinical covariates, all HRV measures, with the exception of the LF/HF ratio, were significantly reduced in subjects with hypertension compared with those with normal blood pressure (Table 2).

Progression to Hypertension
The baseline adjusted HRV values in normotensive men who developed hypertension during 4 years of follow-up were reduced in comparison to those who remained normotensive (Table 3). In women, LF and HF were lower at baseline in those who developed hypertension during follow-up. Table 3 also shows the adjusted OR corresponding to a 1-SD decrement of each HRV measure. These analyses revealed that LF was associated with new-onset hypertension in men (OR, 1.38; 95% confidence interval, 1.04 to 1.83).

On the basis of this model, crude probabilities of progression to hypertension as a function of LF are displayed in Figure 1. This has been plotted for nonsmoking men and women (with mean values for other covariates) at 0.5-SD decremental units. There is a steep curvilinear relation between LF and the incidence of hypertension in men; this relation was less striking in women.

Change in Blood Pressure
The impact of LF on longitudinal blood pressure change as a continuous variable was analyzed using multiple linear re-
study sample through the many years of follow-up. This
strength plays a role in the pathogenesis of hypertension.

Because changes in blood pressure affect autonomic tone
and vice versa, HRV measures differ in hypertensive subjects
when compared with those with normal blood pressure.
Our findings of reduced HRV in systemic hypertension concur
with results from 3 recently published population-based
studies. These studies were either restricted to men or
examined HRV in men and women pooled together and
included subjects on a variety of cardioactive medications.
In contrast, our study included a larger population-based
sample in which referral bias was inherently minimal. We
examined the association between HRV and blood pressure
separately in healthy middle-aged men and women free from
the confounding effects of cardioactive medications.

The absence of a difference in the LF/HF ratio between
normotensive and hypertensive individuals could be ex-
plained by variable responsiveness of the neural regulatory
mechanisms between individuals and the fact that the
LF/HF ratio correlated poorly with other HRV measures.

**Predictors of Hypertension**

After adjustment for age, body mass index, smoking, alcohol
consumption, and baseline systolic and diastolic blood pres-
lures, the LF component of the power spectral analysis
remained predictive of the development of hypertension in
men. Earlier work from Framingham has shown adiposity to
be a strong predictor of hypertension in men and women.
A noteworthy finding in our study was that the LF component
of HRV in men was observed to be a stronger predictor of
hypertension than body mass index, a measure of obesity.
These findings are in contrast to those of a recent study that
identified HF to be a better predictor of incident hypertension
when compared with LF. This difference can be explained
by methodological differences; Liao et al studied ECG
recordings of 2 minutes in duration, which may be insuffi-
cient in length to appropriately measure the LF. The associ-
ation between HF and incident hypertension in that report
was similar in direction but stronger compared with our
study. This could be explained by the fact that the authors did
not adjust for baseline differences in body mass index and
baseline blood pressure in the multivariable estimation of
incident hypertension. A total of 244 subjects developed
hypertension (cumulative incidence of 17%) in the present
report compared with 64 (5%) in the study by Liao et al.

Gender differences in baseline HRV, hormonal changes
accompanying essential hypertension, and cyclic changes of
HRV observed in women may help explain the poorer
predictive value of HRV in women. The weak relation
observed between HRV and diastolic blood pressure as
opposed to systolic blood pressure (Figure 2) could be a
reflection of the low incidence of diastolic hypertension in
the middle-aged Framingham Heart Study population. Subjects
with diastolic hypertension at the index examination also may
have been more likely to receive drug treatment and therefore
be excluded from follow-up for changes in diastolic blood
pressure than those with systolic hypertension; this could
have attenuated the relation between HRV and diastolic blood
pressure.

**Strengths and Limitations**

An important strength of this study is the well-characterized
study sample through the many years of follow-up. This
information allowed us to select subjects who were free of
clinically apparent cardiovascular disease, which can alter
autonomic function and HRV measurements. Additionally,
the relatively large number of subjects who developed hyper-
tension allowed more precise estimation of the risk of
hypertension and permitted adjustment for age and baseline
blood pressure.

This study was based on intermediate-duration recordings,
which yield different values for SDNN than shorter or longer
recordings. The recordings were obtained when subjects
underwent an extensive clinical evaluation and are not rep-
resentative of basal resting conditions. Such activity can precipitate short-term changes in the autonomic tone that can confound the relation of autonomic tone to resting blood pressure measurements. It is uncertain in which direction this would have biased our results.

Clinical Implications

The present study extends the clinical utility of HRV beyond its role in the surveillance of diabetics and patients after myocardial infarction. A reduction in HRV is associated with an increased risk of cardiac mortality and has been shown to predict risk for cardiac events and overall mortality. Additional research is needed to determine whether reduced HRV contributes to the increased cardiac mortality in hypertension. It is possible that an assessment of HRV may help guide the selection of antihypertensive therapy.

Conclusions

HRV is reduced in men and women with systemic hypertension. Among normotensive men, lower HRV was associated with greater risk for developing hypertension. Estimation of LF using spectral analysis of ambulatory ECG recordings improves the prediction of risk of hypertension in men above that which can be obtained from measurements of baseline systolic and diastolic blood pressures, body mass index, and age. These findings are consistent with the hypothesis that autonomic dysregulation is present in the early stage of hypertension.

Acknowledgment

This study was supported by National Institutes of Health/National Heart, Lung, and Blood Institute contract NOI-HC-38038.

References

Reduced Heart Rate Variability and New-Onset Hypertension: Insights Into Pathogenesis of Hypertension: The Framingham Heart Study

Jagmeet P. Singh, Martin G. Larson, Hisako Tsuji, Jane C. Evans, Christopher J. O'Donnell and Daniel Levy

*Hypertension*. 1998;32:293-297
doi: 10.1161/01.HYP.32.2.293

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/32/2/293

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Hypertension* is online at:
http://hyper.ahajournals.org//subscriptions/